Table 2 Correlates of client outcomes regarding cannabis use (Abstinence and ≥ 50% Reductiona)
Variable | Abstinent (n = 17) | Non-abstinent (n = 111) | ORb (95% CI) |  ≥ 50% reduction (n = 31) |  < 50% reduction (n = 97) | ORb 95% CI |
|---|---|---|---|---|---|---|
Duration Regular Use, in decades, M (SD) | 2.22 (1.12) | 1.46 (0.87) | 3.03 (1.36, 7.29) | 1.84 (1.05) | 1.47 (0.89) | 2.87 (1.39, 6.60) |
Gender, n (%) | ||||||
 Female | 9 (30.00) | 21 (70.00) | 4.12c (0.75, 24.30) | 12 (40.00) | 18 (60.00) | 2.10c (0.49, 9.46) |
 Male | 8 (8.25) | 89 (91.75) | 19 (19.59) | 78 (80.41) | ||
 Non-binary | 0 (0.00) | 1 (100.00) | 0 (0.00) | 1 (100.00) | ||
Treatment Groupd, n (%) | ||||||
 Nabiximols | 10 (16.39) | 51 (83.61) | 2.27 (0.50, 11.51) | 20 (32.79) | 41 (67.21) | 4.06 (1.21, 14.95) |
 Placebo | 7 (10.45) | 60 (89.55) | 11 (16.42) | 56 (83.58) | ||
Average quantity of cannabis used, gms, M (SD) | 1.89 (1.54) | 2.41 (2.13) | 0.91 (0.53, 1.42) | 1.66 (1.44) | 2.56 (2.19) | 0.75 (0.46, 1.12) |
Cannabis Problems Questionnaire, z, M (SD) | 0.03 (1.13) | -0.00 (0.98) | 0.72 (0.26, 1.97) | -0.04 (1.00) | 0.01 (1.01) | 0.96 (0.44, 2.09) |
Self-Coping and Efficacy for Quitting, z, M (SD) | 0.29 (1.29) | -0.04 (0.95) | 1.50 (0.75, 3.15) | 0.03 (1.18) | -0.01 (0.95) | 0.85 (0.47, 1.53) |
SF-36 Pain score, z, M (SD) | -0.55 (1.03) | 0.08 (0.97) | 0.41 (0.16, 1–01) | -0.22 (1.01) | 0.07 (0.99) | 0.40 (0.18, 0.83) |
DASS Total Score, z, M (SD) | 0.27 (1.03) | -0.04 (0.99) | 0.98 (0.34, 2.79) | 0.04 (1.08) | -0.01 (0.98) | 0.65 (0.27, 1.50) |
Insomnia Severity Index, z, M (SD) | 0.19 (1.11) | -0.03 (0.98) | 0.68 (0.26, 1.69) | -0.11 (1.09) | 0.03 (0.97) | 0.39 (0.18, 0.82) |
Rate of Counselling Attendance, average number of sessions per fortnight (14Â days), M (SD) | 0.23 (0.22) | 0.11 (0.27) | 5.31 (1.45, 22.19) | 0.18 (0.11) | 0.11 (0.14) | 3.82 (1.30, 12.15) |
Average Dose weeks 2–12, sprays per day, M (SD) | 14.58 (8.08) | 18.70 (9.60) | 0.92 (0.83, 1.01) | 14.68 (8.95) | 19.29 (9.41) | 0.91 (0.84, 0.98) |